Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8126802 | 1.00 | DDB1 (0.40) | DDB1CRBNSLC1A3SLC1A2SLC1A1 | |
| Hydrochloric Acid SCHEMBL5862748 | 0.98 | DDB1 (0.39) | DDB1CRBNSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL9763836 | 0.95 | ALDH1A1 (0.40) | DDB1CRBNSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL5635258 | 0.85 | ALDH1A1 (0.42) | DDB1CRBNALDH1A1 | |
| SCHEMBL7339530 | 0.85 | TDP1 (0.39) | KMT2AMEN1ALDH1A1GLASLC6A2 | |
| SCHEMBL11435272 | 0.84 | DDB1 (0.41) | DDB1CRBNKMT2AALDH1A1GLA | |
| SCHEMBL7313309 | 0.80 | FFAR4 (0.38) | DDB1CRBNGLASLC6A3MAPK1 | |
| SCHEMBL376160 | 0.80 | AKT1 (0.36) | DDB1CRBNL3MBTL1TACR1 | |
| SCHEMBL8690093 | 0.77 | KMT2A (0.40) | KMT2AMEN1SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL7341358 | 0.76 | AKR1C1 (0.38) | KMT2AMEN1ALDH1A1SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130023563-A1 | AMIDINOANILINE DERIVATIVE | AJINOMOTO CO., INC. (JP) | 2013-01-24 | — | — | US | disclosed |
| US-6693072-B2 | Elastase inhibitors | AVENTIS PHARMACEUTICALS INC. | 2004-02-17 | — | — | US | disclosed |
| EP-0804465-B1 | NOVEL ELASTASE INHIBITORS | AVENTIS PHARMA INC (US) | 2003-08-06 | — | — | EP | disclosed |
| US-20030096759-A1 | Novel elastase inhibitors | AVENTISUB II INC. | 2003-05-22 | — | — | US | disclosed |
| CN-1353701-A | Peptidyl heterocyclic ketones useful as tryptase inhibitors | ORTHO MCNEIL PHARM INC (US) | 2002-06-12 | — | — | CN | disclosed |
| WO-1995033763-A1 | NOVEL ELASTASE INHIBITORS | HOECHST MARION ROUSSEL, INC. (US) | 1995-12-14 | — | — | WO | disclosed |
| US-4316906-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1982-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023563-A1 | AMIDINOANILINE DERIVATIVE | F11, SERPINC1, F8 | DDB1 4469/4885CRBN 4746/4885SLC1A3 1879/4885 |
| US-20030096759-A1 | Novel elastase inhibitors | ELANE, SERPINB1, MMP8 | DDB1 1965/4885CRBN 3098/4885SLC1A3 4174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.